NCT06794229: An ongoing trial by Qian Qin
This trial is ongoing. It must report results 3 years, 6 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06794229 |
|---|---|
| Title | A Phase II, Open-label, Single-arm Study of nEoadjuvant Zanzalintinib (XL092) Plus nivoLumab in Patients With lOcally Advanced and/or inopeRable clEar Cell Renal Cell Carcinoma With or Without Non-measurable Metastasis (EXPLORE-RCC) |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Oct. 30, 2025 |
| Completion date | June 30, 2028 |
| Required reporting date | June 30, 2029, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |